“The only thing is that you would rather have a test that tells you which patient responds, not which one doesn't respond. So it's kind of an – other, you know, a different way of looking at things. You know, we're used to, let's say, trying to get a test and say, Yes, you know – this is a tumor that is sensitive to this kind of treatment. Like you get HER2 and, you know, now – we can use Herceptin” (42). The gene discussed is ERBB2; the disease is neoplasm.